We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Chemoembolization for Liver Cancer

By HospiMedica staff writers
Posted on 14 Apr 2005
Two-thirds of liver cancer patients have inoperable tumors and could benefit from a nonsurgical treatment option that delivers a high dose of chemotherapy to a tumor while decreasing blood flow through the arteries feeding the tumor, according to the results of several new studies.

Called chemoembolization, this option allows chemotherapeutic drugs to remain localized to the tumor, decreasing harm to healthy tissues and allowing higher doses of the drugs to be used. More...
Chemoembolization does not induce liver toxicity, the studies showed, but offers patients additional months, and is even safe for high-risk liver cancer patients who already have restricted blood flow in the liver due to portal vein thrombosis.

Although surgical removal of liver tumors offers the best chance for a cure, many are inoperable because they are too large or have grown into major blood vessels or other vital structures. Sometimes, many small tumors are spread throughout the liver, making surgery too risky or impractical. More than two-thirds of liver cancer patients and 90% of those with metastatic cancer cannot have surgery. Doctors need to ensure that cancer treatments do not cause additional liver damage and toxicity.

In chemoembolization, a doctor threads a tiny catheter up the femoral artery in the groin into the blood vessels supplying the liver tumor. The embolic agents keep the chemotherapy drug localized to the tumor while depriving the tumor of blood needed for its growth. The procedure usually involves a hospital stay of two to four days.

"The safety study shows that chemoembolization should be the standard first-line treatment for inoperable liver tumors,” noted Jeff. Geschwind, M.D., director of interventional radiology and associate professor at Johns Hopkins University School of Medicine (Baltimore, MD, USA).




Related Links:
Johns Hopkins School of Medicine

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.